Rose BioSolutions
Rose BioSolutions is a privately held CDMO providing cell and gene therapy developers with GMP plasmid, viral-vector, cellular starting-material manufacturing, and related development services across U.S. and U.K. facilities through project-based contracts.
- Company typePrivate
- Founded2026
- HeadquartersMemphis, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Rose BioSolutions does
Rose BioSolutions is a privately held, PE-backed contract development and manufacturing organization focused on cell and gene therapy. It was formed in May 2026 when GI Partners acquired Charles River Laboratories' CDMO and Cell Solutions businesses. Headquartered in Memphis, Tennessee, Rose operates facilities in Memphis and Rockville, Maryland, and Keele, United Kingdom, with an indicated workforce of roughly 500 employees and 25 GMP suites.
Its service portfolio includes GMP plasmid manufacturing through eXpDNA, AAV vector production through nAAVigation, lentiviral vectors through Lentivation, cellular starting materials through Cell Solutions, and broader cell therapy CDMO services. Rose reports more than 30 years of viral-vector experience, more than 20 years of GMP manufacturing experience, regulatory approvals associated with the FDA, EMA, and MHRA, and 200 GMP-compliant products.
Rose serves more than 35 cell therapy clients. Named examples include AAVantgarde, a small biotechnology company, and the FOXG1 Research Foundation, a nonprofit organization. The business uses quote-based, project-based contracting, and the company is positioned to continue investing in infrastructure, capacity, and technical capabilities while a Charles River partnership for clinical testing continues.
Rose BioSolutions firmographics
Firmographics- Name
- Rose BioSolutions
- Legal name
- Rose BioSolutions
- Website
- https://rosebiosolutions.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Rose BioSolutions is a privately held CDMO providing cell and gene therapy developers with GMP plasmid, viral-vector, cellular starting-material manufacturing, and related development services across U.S. and U.K. facilities through project-based contracts.
- Ownership category
- akta.pro rank
Rose BioSolutions industry classification
Industry- Product category
- Cell and Gene Therapy CDMO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
- akta.pro secondary industries
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Cell Therapy CDMO (HLAGABAD), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
Keywords
Where Rose BioSolutions is headquartered
LocationHeadquarters
- HQ city
- Memphis
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Rose BioSolutions business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- CDMO Manufacturing Services: Contract Development and Manufacturing Organization services including plasmid DNA manufacturing, viral vector manufacturing, and cell therapy manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies developing advanced therapies.
- Cell and Biospecimen Products: Sale of human immune cells, stem cells, leukopaks, GMP-compliant cellular starting materials, and related biological products for research and clinical use.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom CDMO service quotes based on project scope, phase, and grade requirements |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Rose BioSolutions product offering
Product offeringCore offering
Rose BioSolutions is a Contract Development and Manufacturing Organization (CDMO) providing integrated cell and gene therapy manufacturing services across plasmid DNA, viral vectors, and cell therapy production. The company also supplies cellular starting materials (human immune cells, stem cells, leukopaks, and GMP-compliant biological products) for advanced therapy developers. Services span research-grade through GMP-grade production and include process development, analytical development, and regulatory support.
Product overview
Rose BioSolutions offers an integrated portfolio of advanced therapy manufacturing services and cellular starting materials. The core offering centers on CDMO Solutions providing end-to-end Contract Development and Manufacturing Organization services across plasmid DNA manufacturing (via the eXpDNA platform), viral vector manufacturing (via nAAVigation and Lentivation platforms), and cell therapy CDMO services. Complementing these are Cell Solutions for sourcing human immune cells, stem cells, and GMP-compliant cellular starting materials. The company also provides specialized sub-products including off-the-shelf plasmid products, viral vector packaging services, CAR-T manufacturing support, and quality/regulatory services. This unified portfolio enables seamless progression from foundational research materials through clinical to commercial manufacturing.
Differentiator
Problem solved
Functional benefit
Brands
- nAAVigation®: Proprietary adeno-associated viral (AAV) vector production platform that reduces production timelines by over 60%
- Lentivation™
- eXpDNA™
Products and services
- CDMO Solutions End-to-end Contract Development and Manufacturing Organization services for cell and gene therapy developers, spanning from cellular starting materials through plasmid DNA, viral vector production, and cell therapy manufacturing with industry-leading timelines. Targets advanced therapy developers from early-stage research through commercial supply.
- Plasmid DNA Manufacturing Services Fit-for-purpose plasmid production from research to High Quality and GMP grades using the eXpDNA™ platform, supporting all stages of clinical development through commercial supply. Delivers HQ plasmid in as little as 5 weeks and GMP plasmid in 10 weeks from the Keele, UK facility. Serves gene therapy and mRNA developers requiring critical starting materials.
- Viral Vector Manufacturing Services GMP manufacturing of AAV, lentiviral, adenovirus, and retrovirus vectors using the proprietary nAAVigation® and Lentivation™ platforms, reducing production timelines by up to 60% compared to traditional workflows. Serves gene therapy developers requiring reliable viral vector supply for clinical and commercial programs.
- Cell Therapy CDMO Services End-to-end cell therapy manufacturing including process development, analytical development, MSAT functions, and GMP manufacturing for autologous and allogeneic cell therapies across 30+ cell types (CAR-T, NK cells, TILs, MSCs). Operates from 25 dedicated GMP suites in Memphis, TN and supports clinical-to-commercial scale transitions.
- Cell Solutions Cell sourcing capabilities providing human immune cells, stem cells, and GMP-compliant cellular starting materials including leukopaks, PBMCs, bone marrow aspirate, cord blood, iPSCs, and disease-state biospecimens. Built on 45+ years of supplying human cells with a diverse and recallable donor pool, backed by FDA 21 CFR Part 1271, AABB, and CLIA compliance.
- Off-the-Shelf Plasmid Products Premium portfolio of pre-manufactured plasmid products designed for commonly used sequences and configurations to enhance and streamline gene therapy research and discovery programs. Available for immediate purchase by research-stage developers.
- Viral Vector Packaging Services Customizable AAV packaging at multiple scales for every phase of research, and custom lentiviral packaging for HQ and GMP grades. Targets gene therapy researchers and developers requiring vector production without full CDMO program commitment.
Quantifiable outcome
- Up to 60% reduction in viral vector production timelines using proprietary platforms
- +5 more outcomes
Companies that use Rose BioSolutions
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Rose BioSolutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Rose BioSolutions partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Charles River LaboratoriesmajorOngoing long-term commercial partnership between Rose BioSolutions and Charles River provides continued access to clinical testing capabilities. Rose BioSolutions maintains regulatory history, qualifications, and relationships from its Charles River heritage while operating independently.
Scale indicators9 records
Recent moves2 records
Expansion highlights4 records
Rose BioSolutions competitors and assessment
Company assessmentEmerging players
- Genezen: Specialized viral vector and cell therapy CDMO focused on early-stage gene therapy developers; competes with Rose's Rockville viral vector and Memphis cell therapy offerings at the clinical stage.
- Cellares: Emerging cell therapy manufacturing automation company offering integrated cell therapy production platforms; comparable cell therapy focus but differentiated by automation-first model.
Direct peers
- Lonza Cell & Gene Technologies: Global CDMO with the largest cell and gene therapy manufacturing footprint, offering viral vector and cell therapy services that directly compete with Rose BioSolutions across modalities and customer segments.
- Catalent (Novo Holdings): Major cell and gene therapy CDMO with commercial-scale viral vector and cell therapy capabilities, now owned by Novo Holdings; competes head-to-head with Rose for advanced therapy contracts.
- Aldevron (Danaher): Specialized plasmid DNA and viral vector manufacturer serving gene therapy developers; most directly comparable to Rose's Keele plasmid and Rockville viral vector operations.
- AGC Biologics: Cell and gene therapy CDMO with viral vector and cell therapy manufacturing across multiple sites; comparable service portfolio targeting similar advanced therapy clients.
- WuXi Advanced Therapies Unit (WuXi AppTec): Provides plasmid, viral vector, and cell therapy CDMO services globally with a comparable integrated continuum; competes directly with Rose on price, scale, and timeline.
Others
- Vineti (now part of Dawako) / TrakCel: Cell therapy orchestration and chain-of-custody software providers; adjacent ecosystem players supporting the same autologous cell therapy manufacturing workflows Rose serves.
Broad incumbents
- Thermo Fisher Scientific (Patheon/Pharma Services): Diversified life sciences giant with viral vector and cell therapy capabilities embedded in its pharma services segment; competes for biotech CDMO contracts at scale.
- Samsung Biologics: Large-scale biologics CDMO expanding into cell and gene therapy; broader portfolio with massive scale that competes for the largest commercial-stage programs Rose also targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks3 records
Key highlights7 records
Customer concentration
Rose BioSolutions social profiles
Digital presenceRose BioSolutions compliance and trust
Trust signalCompliance8 records
Rose BioSolutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rose BioSolutions leadership team
Management profileNumber of profiles
Rose BioSolutions funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rose BioSolutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rose BioSolutions
What does Rose BioSolutions do?
Rose BioSolutions is a Contract Development and Manufacturing Organization (CDMO) providing integrated cell and gene therapy manufacturing services across plasmid DNA, viral vectors, and cell therapy production. The company also supplies cellular starting materials (human immune cells, stem cells, leukopaks, and GMP-compliant biological products) for advanced therapy developers. Services span research-grade through GMP-grade production and include process development, analytical development, and regulatory support.
Is Rose BioSolutions a public or private company?
Rose BioSolutions is a private company. It is classified as private equity controlled and is currently operating.
When was Rose BioSolutions founded?
Rose BioSolutions was founded in 2026. It employs 501 to 1,000 people.
Where is Rose BioSolutions based?
Rose BioSolutions is headquartered in Memphis, United States, in the North America region.
How does Rose BioSolutions make money?
Two revenue lines are on record. CDMO Manufacturing Services are the primary driver. The others are cell and Biospecimen Products.
Who are Rose BioSolutions's main competitors?
Emerging players on record are Genezen and Cellares. Direct peers are Lonza Cell & Gene Technologies, Catalent (Novo Holdings), Aldevron (Danaher), AGC Biologics and WuXi Advanced Therapies Unit (WuXi AppTec). Vineti (now part of Dawako) / TrakCel is listed as an others. Broad incumbents are Thermo Fisher Scientific (Patheon/Pharma Services) and Samsung Biologics.
Does Rose BioSolutions have an API?
No public API is recorded for Rose BioSolutions.
What industry is Rose BioSolutions in?
Rose BioSolutions's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing). Its NAICS code is 541714 and its SIC code is 8731.